VOR Vor Bio, Inc.

NASDAQ
$23.03

Vor Bio, Inc. (VOR) is expected to report earnings on November 10, 2026, before the market open. The consensus earnings estimate is a loss of $0.85 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -0.3% since its last earnings release on August 11, 2026.

Vor Bio Missed Consensus Estimates
Tuesday, August 11, 2026 · 9:30 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 10
Tuesday · 8:30 AM ET
Earnings Whisper
-
vs ($0.85)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $23.00

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Vor Bio, Inc.

Vor Biopharma Inc. is a cell therapy company pioneering engineered hematopoietic stem cell therapies combined with targeted therapies for the treatment of cancer. Vor Biopharma Inc. is based in CAMBRIDGE, Mass.

Sector

Healthcare

Industry

Biotechnology